DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Immune Tolerance Study With Aldurazyme® (Laronidase)

Information source: Sanofi
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Mucopolysaccharidosis I

Intervention: Laronidase (Biological); Cyclosporine A (CsA) (Drug); Azathioprine (Aza) (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Genzyme, a Sanofi Company

Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Genzyme Europe B.V.

Summary

The purpose of this study is to see if treatment with an antigen-specific immunosuppressive can decrease or stop an antibody response to laronidase (Aldurazyme«) during enzyme replacement therapy with laronidase in severe Mucopolysaccharidosis I (MPS I) participants.

Clinical Details

Official title: A Trial of Antigen-specific Immune Tolerance Induction in Mucopolysaccharidosis I (MPS I) Patients Initiating Enzyme Replacement Therapy With Aldurazyme« (Laronidase)

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Number of Participants Who Achieved Immune Tolerance Induction

Secondary outcome: Percent Reduction of Urinary Glycosaminoglycan (uGAG) Level From Baseline to the End of Treatment/Early Withdrawal

Eligibility

Minimum age: N/A. Maximum age: 5 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Written informed consent is required from the parent(s) or legal guardian(s) prior to

any protocol-related procedures being performed. (A separate informed consent will be requested from the parent(s) for their genotyping, which is independent of the inclusion)

- Participant's parent(s) or legal guardian(s) allow their child's participation and

are willing and able to comply with trial procedures

- The participant must be up to and including 5 years of age at the time of enrollment

- Clinical diagnosis of the severe (Hurler) phenotype of MPS I

- Confirmed presence of 2 nonsense mutations in the alfa-L-iduronidase (IDUA) gene

(that is, compound heterozygosity or homozygosity). For the purpose of enrollment, genotyping may be performed by a local laboratory. If no genotyping is performed by a local laboratory, a sample is collected for analysis by a central laboratory before enrollment

- Documented IDUA deficiency with fibroblast, plasma, serum, leukocyte or dried blood

spot IDUA enzyme activity assay Exclusion Criteria:

- The participant has a clinically significant organ disease including: cardiovascular,

hepatic, pulmonary, neurologic, or renal disease, other serious intercurrent illness or extenuating circumstances that, in the opinion of the investigator, precludes participation in the trial or potentially decrease survival

- The participant has previously received treatment with laronidase

- The participant has known severe hypersensitivity to any excipients of the delivery

solution for laronidase or to any of the other investigational drugs used in the study

- The participant has undergone a haematopoietic stem cell transplant (HSCT),

regardless of outcome, or is currently under consideration for such a transplant. If a family later decides to obtain HSCT, the participant will be discontinued from the trial

- The participant has received an investigational product within the 30 days prior to

enrollment

- The participant has prior treatment in any experimental protocol (for example,

fibroblast injections) that might potentially induce antibodies to laronidase or might affect the interpretation of the participant's antibody response to laronidase

- The participant has received vaccination(s) within 1 month prior to enrollment, or is

unwilling to postpone vaccinations during the Tolerance Induction Period in the trial

- The participant is homozygous for thiopurine methyltransferase (TPMT) deficiency, as

determined by the genotype (the presence of 2 known null alleles for TPMT) or phenotype (near to complete absence of TPMT enzyme activity)

- The participant has a prior history of tuberculosis or a positive test for latent

tuberculosis infection

Locations and Contacts

HCPA, Porto Alegre, Brazil

Moscow Research Institute for Pediatrics and Children Surgery, Moscow, Russian Federation

Additional Information

Starting date: September 2008
Last updated: June 2, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015